The pleiotropic expression of the myotonic dystrophy protein kinase gene illustrates the complex relationships between genetic, biological and clinical covariates of male aging

Aging Male

Volumn 5, Issue 4, 2002, Pages 223-232

  Brisson, D ^b   Houde, G ^b   St Pierre, J ^b   Vohl, M C ^b   Mathieu, J ^b   Gaudet, D ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Androgen; Genetics; Lipid lipoprotein; Myotonic dystrophy; Premature male aging

Indexed keywords

APOLIPOPROTEIN B; FOLLITROPIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PROTEIN KINASE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; AGING; ARTICLE; BIOLOGY; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; COVARIANCE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; FOLLITROPIN BLOOD LEVEL; GENE EXPRESSION; GENETIC TRAIT; HORMONAL REGULATION; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MALE; MEMBRANE DAMAGE; MOLECULAR PHYLOGENY; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; PHYSICAL DISABILITY; PLEIOTROPY; PRIORITY JOURNAL; RATING SCALE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION PROCESS;

EID: 0345700817     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/tam.5.4.223.232     Document Type: Article

References (43)

1. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-8
2. Morales A, Heaton JP, Carson CC 3rd. Andropause: a misnomer for a true clinical entity. J Urol 2000;163:705-12
3. Tan RS, Philip PS. Perceptions of and risk factors for andropause. Arch Androl 1999;43:227-33
4. Harper PS. Myotonic Dystrophy, 3rd edn. Philadelphia: WB Saunders, 2001
5. Aslanidis C, Jansen G, Amemiya C, Shutler G, Mahadevan M, Tsilfidis C, et al. Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 1992;355:548-51
6. Buxton J, Shelbourne P, Davies J, Jones C, Van Tongeren T, Aslanidis C, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992;355:547-8
7. Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355:545-6
8. Mathieu J, Allard P, Potvin L, Prévost C, Bégin P. A 10-years study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999;52:1658-62
9. Mastrogiacomo I, Pagani E, Novelli G, Angelini C, Gennarelli M, Menegazzo E, et al. Male hypogonadism in myotonic dystrophy is related to (CTG)n triplet mutation. J Endocrinol Invest 1994;17:381-3
10. Mastrogiacomo I, Bonanni G, Menegazzo E, Santarossa C, Gennarelli M, Pagani E, et al. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Ital J Neurol Sci 1996;17:59-65
11. Tenover JL. Male hormone replacement therapy including 'andropause'. Endocrinol Metab Clin North Am 1998;27:969-87
12. Deng HW, Chen WM, Recker RR. QTL fine mapping by measuring and testing for Hardy-Weinberg and linkage disequilibrium at a series of linked marker loci in extreme samples of populations. Am J Hum Genet 2000;66:1027-45
13. Gerhold D, Rushmore T, Caskey T. DNA chips: promising toys have become powerful tools. Trends Biochem Sci 1999;24:168-73
14. Mathieu J, De Braekeleer M, Prévost C, Boily C. Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation. Neurology 1992;42:203-8
15. Mathieu J, Boivin H, Bernard PM. The reliability and validity of a muscular disability rating scale in myotonic dystrophy. Neurology 1998;50:A138
16. Mathieu J, De Braekeleer M, Prévost C. Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 1990;40:839-42
17. Gaudet D, Arsenault S, Bélanger C, Hudson TJ, Perron P, Bernard M, et al. Procedure to protect confidentiality of familial data in community genetics and genomic research. Clin Genet 1999;55:259-64
18. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87:589-98
19. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res 1995;43:25-8
20. Goldstein S. In Schneider EL, ed. The Genetics of Aging. New York, USA: Plenum Press, 1978:171-224
21. Johansson A, Henriksson A, Olofsson BO, Olsson T. Adrenal steroid dysregulation in dystrophia myotonica. J Intern Med 1999;245:345-51
22. Johansson A, Carlstrom K, Ahren B, Cederquist K, Krylborg E, Forsberg H, et al. Abnormal cytokine and adrenocortical hormone regulation in myotonic dystrophy. J Clin Endocrinol Metab 2000;85:3169-76
23. Ihara Y, Mori A, Hayabara T, Namba R, Nobukuni K, Sato K, et al. Free radicals, lipids peroxides and antioxidants in blood of patients with myotonic dystrophy. J Neurol 1995;242:119-22
24. Harman D. The aging process. Proc Natl Acad Sci USA 1981;78:7124-8
25. Pugeat M, Fimbel S, Crave JC, Déchaud H, Lejeune H. Hormonal substitution in older men. Horm Res 1995;43:104-10
26. Tibblin G, Adlerberth A, Lindstedt G, Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996;45:1605-9
27. Gaudet D, Moorjani S, Laberge C, Mathieu J, Thibault MC, Morissette J, et al. Plasma LDL Apo B levels in relation to phenotypic expression of myotonic dystrophy. Presented at the Seventh International Congress on Neuromuscular Diseases, Munich, Austria, September 16-22, 1990. J Neurol Sci 1990;98:198
28. Moorjani S, Gaudet D, Laberge C, Thibault MC, Mathieu J, Morissette J, et al. Hypertriglyceridemia and lower LDL cholesterol concentration in relation to apolipoprotein E phenotypes in myotonic dystrophy. Can J Neurol Sci 1989;16:129-33
29. Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 8th edn. New York, USA: McGraw-Hill Book Co, 2000:2835-62
30. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3
31. Laberge C, Gaudet D, Morissette J, Moorjani S, Thibault MC. Linkage of myotonic dystrophy and apo E in a French-Canadian isolate. Cytogenet Cell Genet 1985;81:675-6
32. Thibault MC, Mathieu J, Moorjani S, Lescault A, Prévost C, Gaudet D, et al. Myotonic dystrophy: linkage with apolipoprotein E and estimation of the gene carrier status with genetic markers. Can J Neurol Sci 1989;16:134-40
33. Sabatini DD, Adesnik MB. The biogenesis of membranes and organelles. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 8th edn. New York, USA: McGraw-Hill Book Co, 2000:433-517
34. Morrone A, Pegoraro E, Angelini C, Zammarchi E, Marconi G, Hoffman EP. RNA metabolism in myotonic dystrophy. Patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance. J Clin Invest 1997;99:1691-8
35. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001;29:40-7
36. Murthy V, Julien P, Gagne C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther 1996;70:101-35
37. Isseman I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50
38. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8
39. Sulcova J, Hill M, Hampl R, Starka L. Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulfate in normal subjects. J Endocrinol 1997;154:57-62
40. Sugino M, Ohsawa N, Ito T, Ishida S, Yamasaki H, Kimura F, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-9
41. Tsuji K, Furutama D, Tagami M, Ohsawa N. Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci 1999;65:17-26
42. Gaudet D, Arsenault S, Pérusse L, Vohl MC, St-Pierre J, Bergeron J, et al. Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system using a simple genetic trait. Am J Hum Genet 2000;66:1558-68
43. Gaudet D, Vohl MC, Julien P, Tremblay G, Perron P, Gagne C, et al. Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. Am J Cardiol 1998;82:299-305